NCT02075515View on ClinicalTrials.gov

Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age

PHASE3CompletedINTERVENTIONAL
Enrollment

651

Participants

Timeline

Start Date

August 13, 2014

Primary Completion Date

April 29, 2015

Study Completion Date

April 25, 2016

Conditions
Herpes ZosterHerpes Zoster Vaccine
Interventions
BIOLOGICAL

Herpes Zoster vaccine (GSK 1437173A)

2 doses administered intramuscularly in deltoid region of non-dominant arm.

Trial Locations (8)

2610

GSK Investigational Site, Wilrijk

9000

GSK Investigational Site, Ghent

67207

GSK Investigational Site, Wichita

85213

GSK Investigational Site, Mesa

01757

GSK Investigational Site, Milford

V3K 3P4

GSK Investigational Site, Coquitlam

L6T 0G1

GSK Investigational Site, Brampton

J1H 1Z1

GSK Investigational Site, Sherbrooke

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY